LILLE, France--(BUSINESS WIRE)--ALZPROTECT (http://www.alzprotect.com/en), a biopharmaceutical company developing treatments for Alzheimer’s disease, today ...
Rep. Jennifer Wexton (D-VA) announced that she will not seek reelection in 2024 after having been diagnosed with the rare degenerative disorder progressive supranuclear palsy. The 55-year-old ...
BARCELONA, Spain--(BUSINESS WIRE)--Ferrer, a B Corp-certified international pharmaceutical company, has announced the dosing of the first participant in the Phase II clinical trial, PROSPER. The study ...
This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) in slowing the progression ...
GemVax & Kael Kael announced on the 28th that it has completed patient recruitment for the domestic Phase 2 clinical trial of GV1001, a treatment for progressive supranuclear palsy (PSP). The Phase 2 ...
A clinical trial that will test three drugs concurrently, and could include more, represents new hope for patients with progressive supranuclear palsy (PSP), an incurable neurodegenerative disorder ...
Critical Path Institute (C-Path) today announced the formation of a new task force under its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP ®), dedicated to advancing therapeutic ...
The recent discovery of a unique protein pattern in spinal fluid may make earlier diagnosis of progressive supranuclear palsy a reality. Researchers at the University of California San Francisco (CA, ...
Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are sporadic four-repeat tauopathies that have characteristic clinical and neuropathologic profiles, but also share overlapping ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback